Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10.

Modjtahedi H, Khelwatty SA, Kirk RS, Seddon AM, Essapen S, Del Vecchio CA, Wong AJ, Eccles S.

Br J Cancer. 2012 Feb 28;106(5):883-8. doi: 10.1038/bjc.2012.27. Epub 2012 Feb 7.

PMID:
22315050
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy.

Modjtahedi H, Moscatello DK, Box G, Green M, Shotton C, Lamb DJ, Reynolds LJ, Wong AJ, Dean C, Thomas H, Eccles S.

Int J Cancer. 2003 Jun 10;105(2):273-80.

PMID:
12673691
[PubMed - indexed for MEDLINE]
3.

Specific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma.

McIntyre JB, Bose P, Klimowicz AC, Brockton NT, Petrillo S, Matthews W, Easaw J, Magliocco A, Dort JC.

PLoS One. 2012;7(2):e31723. doi: 10.1371/journal.pone.0031723. Epub 2012 Feb 16.

PMID:
22359620
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.

Modjtahedi H, Komurasaki T, Toyoda H, Dean C.

Int J Cancer. 1998 Jan 19;75(2):310-6.

PMID:
9462724
[PubMed - indexed for MEDLINE]
5.

Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.

Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR.

Cancer Res. 1995 Oct 1;55(19):4375-82.

PMID:
7671250
[PubMed - indexed for MEDLINE]
Free Article
6.

Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.

Modjtahedi H, Eccles S, Sandle J, Box G, Titley J, Dean C.

Cancer Res. 1994 Apr 1;54(7):1695-701.

PMID:
8137284
[PubMed - indexed for MEDLINE]
Free Article
7.

Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study.

Lee HJ, Xu X, Choe G, Chung DH, Seo JW, Lee JH, Lee CT, Jheon S, Sung SW, Chung JH.

Lung Cancer. 2010 Jun;68(3):375-82. doi: 10.1016/j.lungcan.2009.07.014. Epub 2009 Aug 26.

PMID:
19712993
[PubMed - indexed for MEDLINE]
8.

Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer.

Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C, Modjtahedi H.

Int J Oncol. 2005 Aug;27(2):317-25.

PMID:
16010411
[PubMed - indexed for MEDLINE]
9.

Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.

Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC, Gullick WJ, Old LJ, Burgess AW, Scott AM.

Int J Cancer. 2002 Mar 20;98(3):398-408.

PMID:
11920591
[PubMed - indexed for MEDLINE]
10.

Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.

Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, et al.

Cancer Res. 1995 Jul 15;55(14):3140-8.

PMID:
7606735
[PubMed - indexed for MEDLINE]
Free Article
11.

Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance.

Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD.

J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7.

PMID:
15290895
[PubMed - indexed for MEDLINE]
12.

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.

Clin Cancer Res. 2006 Sep 1;12(17):5064-73.

PMID:
16951222
[PubMed - indexed for MEDLINE]
Free Article
13.

The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.

Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM, Furnari FB.

Clin Cancer Res. 2007 Mar 15;13(6):1911-25.

PMID:
17363548
[PubMed - indexed for MEDLINE]
Free Article
14.

Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.

Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM.

Cancer Res. 2001 Jul 15;61(14):5355-61.

PMID:
11454674
[PubMed - indexed for MEDLINE]
Free Article
15.

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).

Klausz K, Berger S, Lammerts van Bueren JJ, Derer S, Lohse S, Dechant M, van de Winkel JG, Peipp M, Parren PW, Valerius T.

Cancer Sci. 2011 Oct;102(10):1761-8. doi: 10.1111/j.1349-7006.2011.02019.x. Epub 2011 Aug 4.

PMID:
21718386
[PubMed - indexed for MEDLINE]
16.

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG.

Clin Cancer Res. 2005 Sep 1;11(17):6390-9.

PMID:
16144944
[PubMed - indexed for MEDLINE]
Free Article
17.

High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC).

Sonnweber B, Dlaska M, Skvortsov S, Dirnhofer S, Schmid T, Hilbe W.

J Clin Pathol. 2006 Mar;59(3):255-9.

PMID:
16505275
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID.

Eur J Cancer. 2010 Jul;46(11):1997-2009. doi: 10.1016/j.ejca.2010.03.036. Epub 2010 Apr 21.

PMID:
20413299
[PubMed - indexed for MEDLINE]
19.

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.

Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, Ritter G, Cohen L, Scanlan MJ, Cavenee WK, Old LJ.

Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):639-44. Epub 2003 Jan 6. Erratum in: Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2163. Cavanee, Webster K [corrected to Cavenee, Webster K].

PMID:
12515857
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Epidermal growth factor receptor expression in ameloblastoma.

Vered M, Shohat I, Buchner A.

Oral Oncol. 2003 Feb;39(2):138-43. Review.

PMID:
12509966
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk